Payment overview · 2025
General Payments
$4,884.87
109 reported records · 23 companies
Healthcare provider profile · identity verified
Eric Yuanchun Zhou, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1689674855
Verified facts
What the public records show
CMS Open Payments records show Eric Yuanchun Zhou, MD received $4,884.87 in general payments during 2025 across 109 reported records.
Gilead Sciences, Inc. accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Jardiance, Kerendia, Linzess, Prolia, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 522 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 287 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $665.23 | 13.6% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $650.32 | 13.3% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $580.21 | 11.9% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $437.28 | 8.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $386.60 | 7.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $374.76 | 7.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $323.14 | 6.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $305.02 | 6.2% | 12 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $164.96 | 3.4% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $150.00 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $143.95 | 3.0% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $124.76 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $120.76 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $117.03 | 2.4% | 5 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $36.62 | 0.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.43 | 0.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.91 | 0.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.91 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.73 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.73 | 0.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.11 | 0.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.41 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,848.25 | 107 |
| Education | $36.62 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $539.03 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $386.60 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $289.24 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $249.76 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $219.82 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $174.34 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $168.46 | 10 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $164.96 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $143.95 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $137.29 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $124.76 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $120.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $117.54 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $117.03 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $103.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $86.50 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.97 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $11.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 104 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 522 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 287 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 101 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 71 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 202 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
71 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
522 | 88 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
287 | 49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
144 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
204 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
100 | 99 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
202 | 118 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
104 | 103 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1649 | 299 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1387 | 249 |
| Losartan Potassium | Losartan Potassium | 1240 | 207 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1093 | 178 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1024 | 182 |
| Alendronate Sodium | Alendronate Sodium | 672 | 129 |
| Vascepa | Icosapent Ethyl | 642 | 108 |
| Metformin Hcl | Metformin Hcl | 586 | 105 |
| Clopidogrel | Clopidogrel Bisulfate | 570 | 96 |
| Metformin Hcl Er | Metformin Hcl | 556 | 100 |
| Finasteride | Finasteride | 532 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 532 | 93 |
| Farxiga | Dapagliflozin Propanediol | 522 | 88 |
| Omeprazole | Omeprazole | 492 | 263 |
| Glipizide Er | Glipizide | 375 | 64 |
| Famotidine | Famotidine | 373 | 118 |
| Gabapentin | Gabapentin | 364 | 174 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 331 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 327 | 194 |
| Meloxicam | Meloxicam | 324 | 191 |
| Pioglitazone Hcl | Pioglitazone Hcl | 312 | 53 |
| Trazodone Hcl | Trazodone Hcl | 310 | 179 |
| Montelukast Sodium | Montelukast Sodium | 306 | 161 |
| Meclizine Hcl | Meclizine Hcl | 291 | 148 |
| Jardiance | Empagliflozin | 287 | 49 |
| Ammonium Lactate | Ammonium Lactate | 280 | 174 |
| Simvastatin | Simvastatin | 268 | 58 |
| Hydrocortisone | Hydrocortisone | 266 | 177 |
| Atenolol | Atenolol | 217 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 32 |
| Vemlidy | Tenofovir Alafenamide | 204 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 202 | 118 |
| Donepezil Hcl | Donepezil Hcl | 178 | 29 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 174 | 84 |
| Januvia | Sitagliptin Phosphate | 158 | 27 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 153 | 59 |
| Synjardy | Empagliflozin/Metformin Hcl | 144 | 18 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 139 | 25 |
| Ursodiol | Ursodiol | 138 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 137 | 87 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 136 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 96 |
| Azelastine Hcl | Azelastine Hcl | 116 | 91 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 112 | 20 |
| Trulicity | Dulaglutide | 112 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 110 | 40 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 108 | 74 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 104 | 103 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 104 | 76 |
| Azithromycin | Azithromycin | 102 | 92 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 102 | 15 |
| Linzess | Linaclotide | 101 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 56 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 100 | 99 |
| Xarelto | Rivaroxaban | 98 | 18 |
| Mupirocin | Mupirocin | 97 | 72 |
| Halobetasol Propionate | Halobetasol Propionate | 94 | 71 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 89 | 17 |
| Fenofibrate | Fenofibrate | 87 | 16 |
| Tradjenta | Linagliptin | 87 | 13 |
| Eliquis | Apixaban | 86 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 55 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 14 |
| Loperamide | Loperamide Hcl | 83 | 54 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 82 | 15 |
| Ezetimibe | Ezetimibe | 82 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 11 |
| Procto-Med Hc | Hydrocortisone | 79 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 13 |
| Allopurinol | Allopurinol | 75 | 15 |
| Amoxicillin | Amoxicillin | 72 | 59 |
| Clotrimazole | Clotrimazole | 71 | 50 |
| Prolia | Denosumab | 71 | 48 |
| Spironolactone | Spironolactone | 71 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 54 |
| Icosapent Ethyl | Icosapent Ethyl | 68 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 67 | 17 |
| Potassium Citrate Er | Potassium Citrate | 65 | suppressed |
| Glipizide | Glipizide | 64 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 59 | 34 |
| Lisinopril | Lisinopril | 59 | 11 |
| Furosemide | Furosemide | 58 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | suppressed |
| Methimazole | Methimazole | 53 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 51 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 48 | 32 |
| Raloxifene Hcl | Raloxifene Hcl | 45 | 11 |
| Entecavir | Entecavir | 44 | suppressed |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 42 | suppressed |
| Felodipine Er | Felodipine | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 35 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | 18 |
| Diclofenac Epolamine | Diclofenac Epolamine | 36 | 19 |
| Mometasone Furoate | Mometasone Furoate | 36 | 17 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 21 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 35 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Ciclopirox | Ciclopirox Olamine | 34 | 11 |
| Celecoxib | Celecoxib | 33 | 24 |
| Folic Acid | Folic Acid | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Acarbose | Acarbose | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Fluocinonide | Fluocinonide | 25 | 18 |
| Naproxen | Naproxen | 25 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 24 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | 19 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 18 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 17 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Benzonatate | Benzonatate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | 12 |
| Sucralfate | Sucralfate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | 11 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Acetic Acid | Acetic Acid | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,884.87 · 109 records | Gilead Sciences, Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, Arikayce, Auvelity, BREZTRI, CAMZYOS, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, Leqembi, Livdelzi, OTEZLA, Ozempic, PENMENVY, PREVNAR 20, PROLIA, RAYALDEE, REPATHA, REZDIFFRA, SHINGRIX, Symbravo, TAVNEOS, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, WATCHMAN, Wegovy, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error